Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).
Ranjan Das, Rajarshi Chakravarty, Varaha V Gantait, Subir Bhattacharjee
Indian Journal of Psychiatry June 1, 2025 DOI: 10.4103/indianjpsychiatry_315_25 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 3 |
| Population | Patients with treatment-resistant depression |
| Intervention | Dextromethorphan-bupropion |
| Duration | 2 weeks |
| Topics | Depression |
| Keywords | Dextromethorphan-bupropion Treatment resistant depression Severe depression New approach Potential solution Standard medications |
| Citations | 4 |
| Key findings | Dextromethorphan-bupropion produced satisfactory response within two weeks in three cases of treatment-resistant depression. |
Abstract
Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.
Comparable studies
Other case reports and case series on depression, most cited first.
Citations in the library
Cited by 2
- Dextromethorphan-bupropion combination in depression with dual diagnosis: Insights from a case series. Indian Journal of Psychiatry February 1, 2026
- Abuse liability of dextromethorphan and its combinatory formulation dextromethorphan/bupropion: a pharmacologic perspective. Expert Opinion on Drug Metabolism & Toxicology 2026
Cites 5
- Management of Treatment-Resistant Depression: Challenges and Strategies Neuropsychiatric Disease and Treatment 2020
- Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry October 19, 2022
- Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder Clinical Psychopharmacology and Neuroscience July 17, 2023
- Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. American Journal of Psychiatry May 18, 2022
- The Effectiveness of Repeated Intravenous Ketamine on Subjective and Objective Psychosocial Function in Patients with Treatment-Resistant Depression and Suicidal Ideation. Journal of Affective Disorders February 1, 2022